Three scientists were recognized by the Lasker Awards for their work on the GLP-1 hormone. Others were honored for work to ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

Amycretin, an oral weight loss drug, led to up to 13% body weight reduction in three months, showing potential for continued ...

Shares of Novo Nordisk NVO gained 4.2% on Sept. 11 after the company presented encouraging detailed efficacy data from the ...

New weight-loss pills cause weight loss almost four times as fast as Ozempic and similar injectable treatments ...

A new drug called amycretin is stepping into the spotlight, boasting impressive results that have both researchers and those ...

Novo Nordisk presented data on its next-generation weight-loss candidate, amycretin, which showed a significant 13% weight ...

Please verify your email address. Whether you're a rookie or a seasoned digital artist, it may be a good idea to forgo purchasing a dedicated drawing tablet and use your existing iPad or Android ...

Obesity costs the health service £6.1 billion ... when people tend to eat more. “Tablets can be more easily stored, made and delivered, so there is great potential,” he said.

NICE has recommended belzutifan for some adults with Von Hippel-Lindau disease, in final draft guidance, which could benefit up to 100 people. Looking back over the journey from our humble beginnings ...

Briggs argues that governments must adopt wide ranging strategies and policies to tackle unhealthy food and obesity.1 Another of the “key commercial drivers of poor diet and ill health” is a lack of ...